PharmTech AI Pulse Check panelists explain why attribution, audit trails, and sign-off matter more than AI watermark detection for GxP quality teams.
|Webcasts|June 18, 2020
Preformulation of Small Molecule Drugs
Author(s)Pace Analytical Sciences
Preformulation studies play a significant role in developing approaches to analytical and formulation development based on the physicochemical properties of small-molecule pharmaceuticals. This webinar will provide insights into the preformulation phase of drug development and will illustrate common issues encountered. Live: Thursday, Jun. 18, 2020 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST On demand available after final airing Jun. 18, 2021 Register free
Register free:
Event Overview:
Preformulation studies play a significant role in developing approaches to analytical and formulation development based on the physicochemical properties of small-molecule pharmaceuticals. Data collected during pre-formulation informs:
- Dosage form selection and design
- Excipient choice
- Understanding of the feasibility of drug product development
- Regulatory strategies
This webcast will provide insights into the preformulation phase of drug development and will illustrate common issues encountered.
Key Learning Objectives:
- To identify the typical experiments performed in preformulation of small molecules
- To recognize how physicochemical properties will affect the choice of dosage form
- To spot potential formulation issues that could have been prevented by pre-formulation activities
Speaker: Frank Koppenhagen, Ph.D., Vice President, Pharmaceutical Development, Pace Analytical Life Sciences
Time and Date: Thursday, Jun. 18, 2020 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST
On demand available after final airing Jun. 18, 2021
Sponsor: Pace Analytical Sciences
Register free:
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Trending on Pharmaceutical Technology
1
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
2
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
3
Symptomatic Dermographism: Novartis Lands Remibrutinib Label Expansion
4
PharmTech AI Pulse Check: Availability Bias Threatens AI Regulatory Reviews
5